(Bloomberg) A top-performing equity fund with years-long investments in the insulin makers behind the recent weight-loss stock frenzy is betting the rally has further to run.Most Read from BloombergVegas’ Newest Resort Is a $3.7 Billion Palace, 23 Years in the MakingTrudeau’s Murder Claim Risks Upending US Courtship of IndiaF-35 Debris Found After a $100 Million Fighter Jet Went MissingIndia, Canada Trade Diplomatic Blows Over Murder AllegationsNovo Nordisk A/S and Eli Lilly & Co. are among t